DOC

VMBIP E-Newsletter 9-18-09

By Laura Sanchez,2014-05-05 15:42
8 views 0
VMBIP E-Newsletter 9-18-09

    VMBIP E-Newsletter, September 18, 2009

    VMBIP Updates

    New Updates

    ? In the August 21, 2009 VMBIP E-Newsletter, we included a bullet announcing that CDC

    was assessing the impact of H1N1 activities on VMBIP activities including VTrckS

    deployment dates based on survey results and other feedback from grantees. Your

    feedback was critical; the overwhelming majority of you requested a delay in VTrckS

    deployment. As a result, we will postpone full VTrckS deployment. The VTrckS delay

    not only supports your needs to focus on H1N1 priorities, but it also provides additional

    time for CDC to implement a comprehensive continuous quality improvement initiative to

    improve the identity proofing process for full VTrckS. We are in the process of planning

    VTrckS next steps, including planning a revised rollout timeline and strategy and

    reassessing the scope of the functionality to be delivered in the initial release of full

    VTrckS. We will develop a frequently asked questions (FAQ) document on the

    implications of the VTrckS delay and will distribute it to you as soon as possible. One

    area we will address in the FAQ document is a brief description of work being done by

    CDC to ensure that the anticipated large volume of H1N1 orders flowing through CDC

    systems (VACMAN, NIPVAC, EDI, SDN, etc.) will be ready to support your H1N1 order

    volumes, given that full VTrckS will not be deployed in time for H1N1 flu vaccine orders.

    If you have any VTrckS questions, please submit them to Nathan Crawford at (404) 639-

    8242 or ncrawford2@cdc.gov; we will utilize your questions to help us develop the FAQ

    document. As always, please copy your POB project officer on any VMBIP/VTrckS

    e-mails.

    Recently Distributed All-Grantee Messages

    Note: Complete messages are included in the Appendix at the end of this e-newsletter.

    ? Please see the all-grantee message dated Friday, September 11, 2009, with the subject

    heading “UPDATE: GlaxoSmithKline (GSK) vaccine availability.”

? Please see the all-grantee message dated Monday, September 14, 2009, with the

    subject heading “New VTrckS OCM and Training Workgroup.”

? Please see the all-grantee message dated Monday, September 14, 2009, with the

    subject heading “GlaxoSmithKline (GSK) HepAB/HepAB18 (Twinrix) vials, availability.”

? Please see the all-grantee message dated Tuesday, September 15, 2009, with the

    subject heading “Influenza Allocation Adjustment Grantee Message.”

? Please see the all-grantee message dated Wednesday, September 16, 2009, with the

    subject heading “GlaxoSmithKline (GSK) DTaPIPV (Kinrix) and HepB-ad (Engerix) vials,

    availability.”

? Please see the all-grantee message dated Wednesday, September 16, 2009, with the

    subject heading “Shipping of seasonal flu vaccine in 72 hour boxes.”

    1

    ? Please see the all-grantee message dated Thursday, September 17, 2009, with the

    subject heading “2009 Program Manager Meeting - 11/16-18/2009; hotel information -

    Hilton, Atlanta, GA.”

    ? Please see the all-grantee message dated Thursday, September 17, 2009 with the

    subject heading “VIS Update.”

As a reminder, VMBIP-related all-grantee messages are posted to the VMBIP Web site at:

    http://www.cdc.gov/vaccines/programs/vmbip/allgranteemessages.htm and

    previous e-newsletters are posted at:

    http://www.cdc.gov/vaccines/programs/vmbip/newsletters.htm.

If you have any questions or comments about the contents of this e-mail, please contact

    Brad Prescott at brad.prescott@cdc.hhs.gov and Julie Orta at julie.orta@cdc.hhs.gov, with a

    copy to your POB project officer.

Brad Prescott

    Project Lead

    Vaccine Management Business Improvement Project

    Immunization Services Division

    Centers for Disease Control and Prevention

    404-639-8796 (direct)

    404-639-8627 (fax)

    brad.prescott@cdc.hhs.gov

2

APPENDIX

From: Santoli, Jeanne (CDC/CCID/NCIRD)

    Sent: Friday, September 11, 2009 2:19 PM

    To: NCIRD Immunization Grantee Mailbox (CDC)

    Cc: Denson, Deberal (CDC/CCID/NCIRD); Hill, Joyalyn (CDC/CCID/NCIRD)

    Subject: UPDATE: GlaxoSmithKline (GSK) vaccine availability

    Importance: High

Grantees,

This message is to provide an update on select products affected by the GlaxoSmithKline (GSK)

    supply constraint issue. {The original all-grantee message highlighting all GSK products affected

    by supply constraints was sent Sep. 1, 2009.} Please note that while this email provides

    information about specific presentation/brand supply constraints so that you will be aware of

    these when you plan your provider orders over the coming months, there are alternative products

    available for the vaccines listed below, and thus there are NOT national vaccine supply shortages for these vaccines that would prevent providers from fully protecting children, adolescents, and

    adults.

    If there are questions, please contact Joy Hill at jkhill@cdc.gov. Havrix, pediatric vials (HepA, NDC 58160-0825-11, 10 pack, single dose vial)

    Status: zero inventory available; currently on backorder at both the McKesson Memphis and

    McKesson Sacramento distribution centers (DCs)

    GSK Resupply: a limited amount of inventory expected to be available at the end of September,

    and then not again until November

    Action:

    a) allow provider orders to remain on backorder until inventory arrives at the McKesson DCs

    b) cancel provider orders

     Note: The ability to order this product has been disabled in VACMAN Havrix, pediatric syringes (HepA, NDC 58160-0825-46, 5 pack, single dose syringe)

    Status: zero inventory available; provider orders currently on backorder at both the McKesson

    Memphis and McKesson Sacramento distribution centers (DCs) GSK Resupply: inventory expected to be available mid-September Action:

    a) allow provider orders to remain on backorder until inventory arrives at the McKesson DCs

    b) cancel provider orders

    Note: The ability to order this product has been disabled in VACMAN Alternate product: Vaqta (Merck HepA, NDC 00006-4831-41, 10 pack single dose vial)

    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Havrix, adult vials (HepA, NDC 58160-0826-11, 10 pack, single dose vial)

    Status: Memphis ~ inventory available

    3

Sacramento ~ zero inventory available; provider orders currently on backorder at McKesson

    Sacramento DC

    GSK Resupply: inventory expected to be available mid-November

    Action:

    a) allow provider orders to remain on backorder until inventory arrives at the McKesson DC

    b) cancel provider orders

    Alternate product: Havrix, adult syringe (HepA-ad, NDC 58160-0826-46, 5 pack, single dose

    syringe)

    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

    Kinrix, vials (DTaP-IPV, NDC 58160-0812-11, 10 pack, single dose vial)

    Status: Memphis: zero inventory available; provider orders currently on backorder at the

    McKesson Memphis DC

    Sacramento: inventory available

    GSK Resupply: inventory expected to be available mid-October

    Action:

    a) allow provider orders to remain on backorder until inventory arrives at the McKesson DCs

    b) cancel provider orders

    Kinrix, syringes (DTaP-IPV, NDC 58160-0812-46, 5 pack, single dose syringe)

    Status: inventory available at both McKesson DCs

    GSK Resupply: inventory expected to be available early to mid-October

    Action: order as needed

     **Note**should inventory become depleted and provider orders go into a backorder status, you

    may wish to a) allow provider orders to remain on backorder until inventory arrives at the

    McKesson DCs; or b) cancel provider orders Alternate product: IPV and DTaP component products are in good supply at both DCs.

    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

    Boostrix, pediatric & adult vials (TDaP, NDC 58160-0842-11/TDaP-ad, NDC 58160-0842-11, 10 pack, single dose vial)

    Status: inventory available at both McKesson DCs

    GSK Resupply: inventory expected to be available early to mid-October

    Action: order as needed

     **Note**should inventory become depleted and provider orders go into a backorder status, you

    may wish to a) allow provider orders to remain on backorder until inventory arrives at the

    McKesson DCs; or b) cancel provider orders Boostrix, pediatric & adult syringes (TDaP, NDC 58160-0842-46/TDaP-ad, NDC 58160-0842-46, 5 pack, single dose syringe)

    Status: Memphis ~ inventory available

    Sacramento ~ zero inventory available; provider orders currently on backorder at McKesson

    Sacramento DC

    4

GSK Resupply: inventory expected to be available early to mid-October

    Action:

    a) allow provider orders to remain on backorder until inventory arrives at the McKesson DC

    b) cancel provider orders

    Alternate products: Adacel (Sanofi TDaP/TDaP-ad, NDC 49281-0400-10, 10 pack, single dose

    vial) Adacel (Sanofi TDaP/TDaP-ad, NDC 49281-0400-15, 5 pack, single dose syringe) ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Rotarix (ROTA, NDC 58160-0805-11)

    Doses arrived last week at McKesson; additional re-supply for US anticipated mid-September.

    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ To cancel provider orders, please contact McKesson Customer Service.

     McKesson Customer Service:

     877.822.7746

     CDCCustomerService@McKesson.com

    Feel free to contact Joy Hill at jkhill@cdc.gov with questions.

    5

    From: Crawford, Nathan (CDC/CCID/NCIRD) Sent: Monday, September 14, 2009 11:19 AM To: NCIRD Immunization Grantee Mailbox (CDC) Cc: Prescott, Brad (CDC/CCID/NCIRD); Geoghagan, Randal R. (CDC/CCID/NCIRD)

    (CTR) Subject: New VTrckS OCM and Training Workgroup

A new VTrckS Grantee Advisory Committee (GAC) workgroup will begin on Tuesday,

    September 22.

This new workgroup is the Organizational Change Management and Training Workgroup.

These will be the primary roles of this group:

    ? Working with Training Team on training strategy for Grantees (centralized, regional, or local)

    ? Working with Training Team on evaluating training material and curriculum being developed

    for Grantees

    ? Recommending training approach for Grantee training (Web Based, Instructor led, Quick

    reference, etc)

    ? Evaluating role definition process (how roles will be developed in the system and established

    across all grantees) as it relates to the Grantee office

    ? Recommending approaches for all Readiness Workshops (General Education, Business

    Impact, etc.)

    ? Change Agent Identification

The CDC lead for this new GAC group is Brad Prescott. Please send either Brad Prescott

    (bap3@cdc.gov) or Nathan Crawford (ncrawford2@cdc.gov) an email if you are interested in

    volunteering your time on this important workgroup.

6

    From: Santoli, Jeanne (CDC/CCID/NCIRD) Sent: Monday, September 14, 2009 8:23 PM To: NCIRD Immunization Grantee Mailbox (CDC) Cc: Hill, Joyalyn (CDC/CCID/NCIRD) Subject: GlaxoSmithKline (GSK) HepAB/HepAB18 (Twinrix) vials, availability

Grantees,

    This message is to inform you that GSK HepAB/HepAB18, vial presentation, has been disabled in

    VACMAN.

GSK HepAB/HepAB18 (Twinrix) vials, NDC 58160-0815-11, 10 pack-single dose vial

    Status: zero inventory at both the McKesson Memphis and McKesson Sacramento Distribution

    Centers (DCs)

Resupply: bulk replenishment orders have been placed with manufacturer; anticipate arrival at

    DCs later this week

Action: none; provider orders currently in a backorder status will be released for delivery when

    bulk replenishment orders are received at DCs

The ability to place provider orders in VACMAN will be enabled when bulk replenishment orders

    are received at the DCs.

Alternate product: GSK HepAB/HepAB18 (Twinrix) syringes, NDC 58160-0815-46, 5 pack-single

    dose syringe

Feel free to contact Joy Hill at jkhill@cdc.gov with questions.

    7

    Subject: Influenza Allocation Adjustment Grantee Message Date: Tuesday, September 15, 2009

Dear Grantees:

The allocated influenza doses have had adjustments completed Monday September 14, 2009 to

    synchronize the CDC and McKesson systems. These changes will be reflected in the daily flu

    allocation report for Tuesday September 15, 2009.

For two products, allocations were reduced slightly because the amount of doses available at the

    depots was less than previously entered into the allocation tool. You will also see some

    increases as well for products that have been received since the last allocation update.

We apologize for any inconvenience this may cause, and have put mechanisms in place to

    monitor the daily activity between the CDC and McKesson systems so that this type of

    adjustment will not be needed in the future.

If you have questions about your allocation report, please contact Nikki Williams

    (nwilliams1@cdc.gov) or Lisa Galloway (lgalloway@cdc.gov).

Thanks, Jeanne

8

    From: Santoli, Jeanne (CDC/CCID/NCIRD) Sent: Wednesday, September 16, 2009 7:18 PM To: NCIRD Immunization Grantee Mailbox (CDC) Cc: Denson, Deberal (CDC/CCID/NCIRD); Hill, Joyalyn (CDC/CCID/NCIRD);

    Galloway, Lisa (CDC/CCID/NCIRD); Somerfeldt, Sally (CDC/CCID/NCIRD);

    Kuykendall, Helen (CDC/CCID/NCIRD) Subject: GlaxoSmithKline (GSK) DTaPIPV (Kinrix) and HepB-ad (Engerix) vials,

    availability

Grantees,

    This message is to inform you that GSK DTaPIPV, vial presentation, and HepB -adult, vial

    presentation, have been disabled in VACMAN.

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

    GSK DTaPIPV (Kinrix) vials, NDC 58160-0812-11, 10 pack-single dose vial

    Status: zero inventory at both the McKesson Memphis and McKesson Sacramento Distribution

    Centers (DCs)

Resupply: bulk replenishment orders have been placed with manufacturer; anticipate arrival at

    DCs in mid-October

Action: cancel any provider orders for this product which are in a "backorder" status**

     McKesson Customer Service:

     877.822.7746

     CDCCustomerService@McKesson.com

    **NOTE**: Any orders currently in a backorder status should be cancelled by the grantee by COB Wednesday, September 23, 2009. Any remaining orders will be cancelled on September

    24th.

Alternate product: GSK DTaPIPV (Kinrix) syringes, NDC 58160-0812-46, 5 pack-single dose

    syringe

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

    GSK HepB-adult (Engerix) vials, NDC 58160-0821-11, 10 pack-single dose vial

    Status: zero inventory at both the McKesson Memphis and McKesson Sacramento Distribution

    Centers (DCs)

Resupply: bulk replenishment orders have been placed with manufacturer; anticipate arrival at

    DCs at the end of September

Action: none; provider orders currently in a backorder status will be released for delivery when

    bulk replenishment orders are received at DCs

The ability to place provider orders in VACMAN will be enabled when bulk replenishment orders

    are received at the DCs.

Alternate product: GSK HepB-a (Engerix) syringes, NDC 58160-0821-46, 5 pack-single dose

    syringe

Feel free to contact Joy Hill at jkhill@cdc.gov with questions.

    9

    From: Santoli, Jeanne (CDC/CCID/NCIRD) Sent: Wednesday, September 16, 2009 3:55 PM To: NCIRD Immunization Grantee Mailbox (CDC) Cc: Kuykendall, Helen (CDC/CCID/NCIRD); Somerfeldt, Sally (CDC/CCID/NCIRD);

    Galloway, Lisa (CDC/CCID/NCIRD); 'Silvers, Scott'; Hopwood, Steve I Subject: Shipping of seasonal flu vaccine in 72 hour boxes

Dear Grantees,

During flu season McKesson will be shipping on Saturdays and Sundays. To ensure viability of

    seasonal flu vaccine, McKesson will be using 72-hour boxes as needed, so some of your

    providers may see flu and non-flu shipments arriving in both 72- and 48-hour boxes. Alaska,

    Hawaii, Puerto Rico, the Pacific Islands, and the US Virgin Islands will continue to receive

    shipments in 72-hour boxes only (please refer to the attached all-grantee message dated June 1,

    2009).

    Neither the 72- nor the 48-hour box is to be returned to McKesson, so please use local recycling

    for box disposal.

If you have questions, please contact Helen Kuykendall via email at htk0@cdc.gov or your POB

    project officer.

Thanks.

*****************************************************************************************************

    NOTE: The all-grantee message dated June 1, 2009, has been copied and pasted below.

From: Nancy Fasano

    Sent: June 1, 2009

    Subject: IMPORTANT! Upcoming Change in Vaccine Shipment Boxes

Dear Grantees:

In the last half of June, McKesson will begin shipping vaccine orders in a new box using the

    phased in approach outlined below. This new box has been thoroughly tested in laboratory

    conditions as well as real world shipping conditions and meets with approval from the

    CDC. McKesson collaborated with an independent firm with cold chain technology expertise to

    conduct this testing.

    The biggest change is that your providers will no longer return shipping boxes to McKesson for

    recycling/reuse. Therefore the boxes no longer have pre-printed return address labels.

    McKesson recommends providers keep one or two boxes for any expired or non-viable vaccine

    returns to McKesson. If providers need to return expired or non-viable product to McKesson, you

    should contact Customer Service at 1-877-822-7746, and a representative will schedule a pick up

    and send out a return label.

    McKesson plans on implementing the new box using a phased-in approach. The timeline for

    implementation will be as follows:

    o Approximately 20% of all orders 6/22/09 7/1/09

    o Approximately 40% of all orders 7/1/09 7/14/09

    o Approximately 60% of all orders 7/14/09 7/30/09

    10

Report this document

For any questions or suggestions please email
cust-service@docsford.com